Antifungal Treatment Market Research Report by Drug Class (Azoles, Echinocandins, Polyenes, Allylamine, Pyrimidines, and Others), by Technology (Oral, Topical, and Parenteral), by Indication (Dermatophytosis, Aspergillosis, Candidiasis, Invasive Candidiasis, Vulvovaginal Candidiasis, Mouth/Throat/Esophageal Candidiasis, and Others), by Pathogen (Candida, Aspergillus, Cryptococcus, Coccidioides Immitis, Zygomycetes, Trichophyton, and Others), by Pathogen (Hospitals & Clinics, Dermatology Clinics, and Others), and by Region (North America, Eu

Antifungal Treatment Market Overview

The Antifungal Treatment Market size was valued at USD 16.85 billion in 2023 and is projected to grow from USD 16.85 billion in 2024 to USD 17.5054 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.89% during the forecast period (2024 - 2032). The increasing incidence of fungal infections and the rising prevalence of immunological diseases are positively contributing to the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
October 2023:

 Basilea Pharmaceutica Ltd, a biopharmaceutical company focused on treating severe bacterial and fungal infections, has announced that it has entered into an agreement with Gravitas Therapeutics Inc. to purchase the assets of GR-2397. GR-2397 is a clinical-stage antifungal compound that works in a unique way to combat invasive mold infections caused by Aspergillus species. 

The addition of an antifungal drug to the pipeline, previously known as GR-2397 but now called BAL2062, has successfully undergone a clinical phase 1 investigation. Due to its unique method of action that leads to fast killing of fungus in laboratory settings, BAL2062 has the potential to be a beneficial therapy choice for challenging invasive mold infections. 

In order to determine the best strategic placement and the most effective approach for clinical development, they will commence a targeted preclinical profiling effort. After successfully completing the preclinical profiling, they want to proceed immediately to phase 2 clinical development in the first part of 2025.

May 2022:

Bayer's Consumer Health division has introduced an enhanced line of Canesten, its antifungal treatment solution, in India. The product variety is offered in both powder and cream formulations, and it contains anti-fungal characteristics that aid in the prevention and treatment of skin infections. Canesten is a user-friendly remedy that effectively controls skin infections. 

It not only relieves itching but also stops the illness from spreading. Canesten anti-fungal dusting powder is utilized for the prevention, treatment, and subsequent management of superficial skin fungal infections. It offers five times more alleviation compared to regular talcum powder in alleviating symptoms such as prickly heat, redness, skin irritation, itching, and fungal infection. Canesten cream alleviates symptoms of several fungal skin illnesses, including ringworm, jock itch, cutaneous candidiasis, athlete's foot, erythrasma, and fungal nail infection.

Antifungal Treatment Market Trends

• Increasing incidence of fungal infections

 Fungal infections encompass both systemic and superficial infections, including infections of the skin, eye, mouth, and vagina. Antifungal products with fungicidal activity are mostly used to treat a wide array of diseases, such as athlete's foot, ringworm, and fungal meningitis, caused by fungal agents. According to the Centers for Disease Control and Prevention (US), more than 75,000 hospitalizations and nearly 9 million outpatient visits occur every year for fungal diseases in the US.

Moreover, there are several products available associated with different routes of administration on the market for the treatment of fungal infections, such as oral and intravenous medicines, creams, sprays, shampoos, solutions, pessaries, and injections. In addition, increasing launches of innovative products is further fueling the growth of the market. For instance, in May 2022, Bayer AG (Germany) launched a new and improved Canesten antifungal treatment solution in India. The product line, which is available in powder and cream forms, has anti-fungal properties that aid in the prevention and treatment of skin infections. The antifungal cream provides relief from infection, and the mild steroid cream reduces the inflammation due to infection.

Hence, the high availability of different routes of administration and the rising prevalence of different types of fungal infections are fostering market growth.

Antifungal Treatment Market Segment Insights

Antifungal Treatment Market Drug Class Insights

Based on drug class, the Antifungal Treatment Market is segmented into azoles, echinocandins, polyenes, allylamine, pyrimidines, and others. The azoles segment held the largest market share in 2022, and the polyenes is anticipated to register the highest CAGR from 2024 to 2032. Azoles play a crucial role in the growth of the antifungal disease treatment market due to their effectiveness in combating fungal infections. Azoles are a class of antifungal drugs that inhibit the growth of fungi by interfering with the synthesis of ergosterol, a vital component of fungal cell membranes. 

The key factors that drive the growth of this segment are broad spectrum of activity of azoles, different administration routes, and increasing prevalence of fungal infections. According to preliminary Centers for Disease Control and Prevention (CDC) data in 2022 reported there were about 2,377 cases of Candida Auris across the U.S. Thus, increase in fungal infections has led to an increase in the demand of azoles drugs across the world for effective antifungal treatment which drives the growth of market.

Antifungal Treatment Market Route of Administration Insights

Based on the route of administration, the Antifungal Treatment Market has been segmented into oral, topical, and parenteral. Topical held the largest market share in 2022 and parenteral is anticipated to register the highest CAGR from 2024 to 2032. The segment market growth is attributed to increasing prevalence of fungal infections, rising consumer awareness towards fungal infections and limited systemic side effects drive the key growth of the antifungal treatment market. 

Furthermore, the launch of innovative products in the market to meet patients and healthcare professionals’ demand is burgeoning the route of administration segment. For instance, in March 2022, Mundipharma (UK) and Cidara Therapeutics, Inc. (US) received an approval from Medicines and Healthcare Products Regulatory Agency (MHRA) for Rezafungin for the treatment of invasive candidiasis

Antifungal Treatment Market Indication Insights

The Antifungal Treatment Market, based on the indication, has been segmented into dermatophytosis, aspergillosis, candidiasis, invasive candidiasis, vulvovaginal candidiasis, mouth/throat/esophageal candidiasis, and others. Candidiasis held the largest market share in 2022, and

dermatophytosis

is anticipated to register the highest CAGR from 2024 to 2032. 

The segment market growth is driven by the increasing prevalence of candidiasis, and growing awareness and diagnosis drive the key growth of the antifungal treatment market. Moreover, there is an increase in the launch of new options to treat patients with candidiasis, a deadly fungal infection. For instance, in March 2023, Cidara Therapeutics, Inc. (US) and Melinta Therapeutics, LLC (US) received US Food and Drug Administration approval for REZZAYO for the treatment of invasive candidiasis in adults with limited or no alternative treatment options, furthering creative flourishing opportunities for the market.

FIGURE 2: ANTIFUNGAL TREATMENT MARKET, BY INDICATION, 2023 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Antifungal Treatment Market Pathogen Insights

Based on pathogens, the Antifungal Treatment Market is segmented into candida, aspergillus, cryptococcus, coccidioides immitis, zygomycetes, trichophyton, and others. Candida held the largest market share in 2022, and cryptococcus is anticipated to register the highest CAGR from 2024 to 2032. 

The segment’s growth is attributed to the increasing prevalence of vulvovaginal candida and increasing women's healthcare awareness towards candida infections, which drive the key growth of the antifungal treatment market. 

For instance, according to the National Institute of Health, in 2022, it was estimated that about 138 million women globally experienced recurrent vulvovaginal candida annually.

Antifungal Treatment Market End User Insights

The Antifungal Treatment Market, based on the end user, has been segmented into hospitals & clinics, dermatology clinics, and others. Dermatology clinics held the largest market in 2022 with a market share of 47.73% due to rise in the number of patient visits suffering from skin fungal infection across the world boosting the growth of market. 

Moreover, hospital and clinics segment exhibited the highest growth in the forecast period owing to increase in the demand for antifungal drugs among hospital and clinics for the treatment of various fungal disease drives the growth of market.

Antifungal Treatment Market Regional Insights

By region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America accounted for the largest market share of over 40% in 2022 is owing to various factors and one of them is increasing number of people with fungal infections. Moreover, market players are forming strategies to distribute and sell antifungal medicine in the US. For instance, in March 2023, GlaxoSmithKline PLC (UK) entered into an agreement with Scynexis, Inc. (US) to commercialize and develop Brexafemme (ibrexafungerp), a first-in-class medicine to treat antifungal in the US.

Further, the major countries studied are: The US, Canada, Germany, France, the UK, Italy, Spain, China, India, Japan, South Korea, Australia, Brazil.

FIGURE 3: ANTIFUNGAL TREATMENT MARKET, BY REGION, 2023 & 2032 (USD MILLION)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

The Europe anti-fungal infection market growth is driven by majorly invasive fungal infections, which have been dramatically increasing since the last decade in the European countries. Moreover, patients with hematologic malignancies and hematopoietic cell transplant recipients (HCT) are found to get invasive fungal infections in the European population. 

Furthermore, as per the Eurosurveillance, an increasing number of cases of Candida auris have been reported in 2021 and 2022 in countries such as France, Germany, Greece, Italy, the Netherlands, Spain, Belgium, and Austria. Furthermore, the Germany antifungal treatment market held the largest market share in 2022 and UK antifungal treatment market is the fastest growing market in the Europe region.

The Asia-Pacific anti-fungal treatment market is the fastest-growing region during the forecast period owing to increasing fungal infection cases in Asian countries. In 2020, the Global Action for Fungal Infections (GAFFI) and Fudan University (Shanghai) estimated that one million people suffer from invasive aspergillosis in China each year. The populations at risk of invasive aspergillosis are those with lung cancer,

chronic obstructive pulmonary diseases

, pulmonary tuberculosis, acute myelogenous leukemia, and the late stage of the human immunodeficiency virus. 

Additionally, fungal infections are more common in tuberculosis patients, thus increasing the incidence of tuberculosis diseases (TB), which is driving the region’s growth. As per the World Health Organization (WHO) Global TB Report 2022, in India, 210 per 1,000,000 people were diagnosed with TB in 2021. Moreover, China antifungal treatment market held the largest market share in 2022 and India antifungal treatment market is the fastest growing market in the Asia-Pacific region.

Antifungal Treatment Market Key Market Players & Competitive Insights

The anti-fungal treatment market is distinguished by the presence of numerous, local players catering to medical devices that are evolving at a rapid pace. The increasing incidents of fungal infections, increasing prevalence of immunological diseases in the anti-fungal treatment, and the availability of wide range of products are further expected to drive the growth of the anti-fungal treatment market during the forecast period. However, the side-effects of treatment may hamper the growth of the anti-fungal treatment market.

The major players have adopted a strategy of obtaining regulatory approval from government agencies for their drugs and signing contracts and agreements to broaden their reach and reduce operational costs. Moreover, the anti-fungal treatment market is extremely competitive, with players competing, partnering, and investing heavily in R&D to gain a significant market share. The market is moderately fragmented with rising competition, product launches, increasing collaborative partnerships, and other strategic decisions to achieve operational efficiency.

Pfizer, Inc. (US) manufactures and develops vaccines and medicines for a wide range of medical disciplines that include oncology, cardiology, immunology, diabetology/endocrinology, and neurology. Pfizer also collaborates with healthcare providers, governments, and local communities to support and broaden access to high-quality, reasonably priced healthcare globally. Pfizer distributes its goods through distributors, retailers, hospitals, clinics, public institutions, and pharmacies. The company has R&D platforms in the field of biosimilars,

gene therapy

, precision medicines, and medicinal sciences. 

Furthermore, the company supplies its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Moreover, in April 2021, the company acquired the biotech firm Amplyx Pharmaceuticals (US) to add more anti-infective drugs to its pipeline and develop antifungal medications. The company's main component, fosmanogepix, is an inventive investigational antifungal that is being created to treat invasive fungal infections.

Key Companies in the Antifungal Treatment Market includes.

• Pfizer Inc (US)


• 
  Johnson & Johnson Services, Inc (US)


• Bayer AG (Germany)


• Novartis AG (Switzerland)


• Abbott Laboraotories, Inc. (US)


• Merck KGaA (Germany)


• Gilead Sciences, Inc (US)


• Cipla, Inc. (India)


• Sanofi S.A. (France)


• GlaxoSmithKline Plc (UK)

Antifungal Treatment  Industry Developments

March 2023:

GlaxoSmithKline plc (UK) announced agreement with SCYNEXIS, Inc (US) to commercialize and further develop Brexafemme (ibrexafungerp) for the treatment of fungal infection.

March 2023:

Sanofi S.A. (France) announced that it received European commission approval for its product “Dupixent” for the children in case of severe atopic dermatitis.

May 2022:

Bayer AG (Germany) has relaunched the antifungal brand Canesten in India to assist consumers treat and prevent skin and foot infections globally. The product line's anti-fungal properties help treat and prevent skin problems. According to a statement from Bayer, Canesten is an easy-to-use formulation for treating full-cycle skin infections that not only reduces itching but also halts the spread of infection.

December 2020:

Sanofi S.A. (France) renewed a new five-year USD 25 million partnership with the World Health Organization (WHO) to fight Neglected Tropical Diseases. Neglected tropical diseases (NTDs) refer to a group of parasitic, bacterial, fungal, and viral diseases that affect or threaten over one billion people worldwide.

Antifungal Treatment Market Segmentation

Antifungal Treatment Market Drug Class Outlook

• Azoles


• Echinocandins


• Polyenes


• Allylamine


• Pyrimidines


• Others

Antifungal Treatment Market Route of Administration Outlook

• Oral


• Topical


• Parenteral

Antifungal Treatment Market Indication Outlook

• Dermatophytosis


• Aspergillosis


• Candidiasis


• Invasive Candidiasis


• Vulvovaginal Candidiasis


• Mouth/Throat/Esophageal Candidiasis


• Others

Antifungal Treatment Market Pathogen Outlook

• Candida


• Aspergillus


• Cryptococcus


• Coccidioides Immitis


• Zygomycetes


• Trichophyton


• Others

Antifungal Treatment Market End User Outlook

• Hospitals & Clinics


• Dermatology Clinics


• Others

Antifungal Treatment Market Regional Outlook

North America

• US


• Canada

Europe

• Germany


• France


• UK


• Italy


• Spain


• Rest of Europe

Asia-Pacific

• China


• India


• Japan


• South Korea


• Australia


• Rest of Asia-Pacific

Rest of the World

• Middle East


• Africa


• Latin America

Attribute/Metric	Details
Market Size 2023	USD 16.85 billion
Market Size 2024	USD 17.5054 billion
Market Size 2032	USD 23.76 billion
Compound Annual Growth Rate (CAGR)	3.89% (2024-2032)
Base Year	2023
Forecast Period	2024-2032
Historical Data	2019 & 2022
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Drug Class, Route of Administration, Indication, Pathogen, End User, and Region
Geographies Covered	North America, Europe, Asia Pacific, and Rest of the World
Countries Covered	The US, Canada, Brazil, Germany, France, the UK, Italy, Spain, China, India, Japan, South Korea, Australia.
Key Companies Profiled	Pfizer Inc (US), Johnson & Johnson Services, Inc (US), Bayer AG (Germany), Novartis AG (Switzerland), Abbott Laboraotories, Inc. (US), Merck KGaA (Germany), Gilead Sciences, Inc (US), Cipla, Inc. (India), Sanofi S.A. (France), and GlaxoSmithKline Plc (UK)
Key Market Opportunities	·       Development of new drugs
Key Market Drivers	·       Increasing incidence of fungal infections·       Increasing prevalence of immunological diseases·       Availability of wide range of products